Results 51 to 60 of about 629,742 (317)

Transplantation immunology: aspects of allo- and EBV-specific reactivity : the EBV non-infected elderly - factors of resistance [PDF]

, 2010
Defining the relevant components of cellular alloimmunity remains an important unresolved issue in clinical transplantation. The most promising marker of cellular alloreactivity available to date is donor-specific secretion of interferon-gamma (IFN-) as ...
Durovic, Bojana
core   +1 more source

Prevalence of 21 Physician‐Defined Severe Toxicities Following Childhood Acute Lymphoblastic Leukemia Treatment: Australian Retrospective Cohort Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with an overall survival now surpassing 90% in developed countries. However, treatments are not without adverse effects. In this study, we apply the severe toxicity‐free survival (STFS) framework to determine the prevalence of 21 physician‐defined severe ...
Lane Collier, Brittany Grantham, Camilla Grud Nielsen, Louise Lundgren, Liv Andrés‐Jensen, Kjeld Schmiegelow, Chris Selman, Gareth Ball, Elyse Passmore, David A. Elliott, Rachel Conyers   +10 more
wiley   +1 more source

Determination of the therapeutic time window for human umbilical cord blood mononuclear cell transplantation following experimental stroke in rats [PDF]

, 2022
34 S.Experimental treatment strategies using human umbilical cord blood mononuclear cells (hUCB MNCs) represent a promising option for alternative stroke therapies.
Strassburger, M., Förschler, A., Schäbitz, W.-R., Boltz, J., Schmidt, U.R., Kranz, A., Reich, D.M., Reymann, K.G., Wagner, D.-C., Lobsien, D.   +9 more
core   +1 more source

Improved Early Referral in Long‐Term Survivor Care With Institutional Standardized Practice Among Childhood Leukemia Survivors#

Pediatric Blood &Cancer, EarlyView.
ABSTRACT In 2018, the Texas Children's Cancer and Hematology Center Leukemia Program implemented a practice standard to support the transition from treatment to survivorship that includes shared, alternating care between leukemia and survivorship clinicians and a reminder to refer survivors to the long‐term survivor clinic (LTSC) 2 years after ...
Ji Yun Tark, Kayla L. Foster, Omar Shakeel, Mary C. Shapiro, Shawki L. Qasim, ZoAnn Dreyer, Eric S. Schafer, Ashley M. Butler, Austin L. Brown, Maria Monica Gramatges   +9 more
wiley   +1 more source

MLL-SEPT5 Fusion Transcript in Myelodysplastic Syndrome Patient With t(11;22)(q23;q11)

Frontiers in Medicine, 2021
Objectives: This study aimed to identify unknown mixed lineage leukemia (MLL) translocation partner genes in a de novo patient with myelodysplastic syndrome (MDS) with t(11;22)(q23;q11) and investigate the clinical and molecular features of this patient ...
Duobing Zou, Ying Chen, Ningning Wu, Yi Zhang, Guifang Ouyang, Qitian Mu   +5 more
doaj   +1 more source

B Cells and Antibodies in Transplantation [PDF]

Transplantation, 2016
Overlooked for decades, the humoral alloimmune response is increasingly recognized as a leading cause of graft loss after transplantation. However, improvement in the diagnosis of antibody-mediated rejection has not yet translated into better outcomes for transplanted patients.
Alice, Koenig, Christophe, Mariat, Christiane, Mousson, Kathryn J, Wood, Gérard, Rifle, Olivier, Thaunat   +5 more
openaire   +3 more sources

Personalized Zebrafish Models for Fusion‐Positive Pediatric Sarcomas

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Clinical sequencing efforts have revolutionized our approaches to categorizing pediatric cancers in real time. This has dramatically improved our ability to profile pediatric tumors, identify actionable vulnerabilities, and influence clinical care.
Lisa H. Hall, Emma N. Harrison, Genevieve C. Kendall   +2 more
wiley   +1 more source

One novel ACOT7–NPHP4 fusion gene identified in one patient with acute lymphoblastic leukemia: a case report

BMC Medical Genomics, 2022
Background Acute lymphoblastic leukemia (ALL) is a type of heterogeneous hematopoietic malignancy that accounts for approximately 20% of adult ALL. Although ALL complete remission (CR) rate has increased to 85–90% after induction chemotherapy, 40–50% of ...
Xin Zong, Zhijie Kang, Dan Huang, Xuehong Zhang, Yuan Gao, Haina Wang, Weiling Li, Jinsong Yan   +7 more
doaj   +1 more source

JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?

Hematology, 2022
Objectives BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.
Francesco Tarantini, Cosimo Cumbo, Antonella Zagaria, Elisa Parciante, Luisa Anelli, Nicoletta Coccaro, Giuseppina Tota, Crescenzio Francesco Minervini, Immacolata Redavid, Antonella Russo Rossi, Maria Rosa Conserva, Giorgina Specchia, Pellegrino Musto, Francesco Albano   +13 more
doaj   +1 more source

The Role of “Adult‐Onset” Cancer Predisposition Genes in Pediatric Cancer: A Comprehensive Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Current literature estimates that 10% of pediatric cancers are caused by pathogenic or likely pathogenic (P/LP) germline variants in cancer predisposition genes (CPGs). Variants in CPGs thought to increase cancer risk exclusively during adulthood are referred to as “adult‐onset” CPGs (aoCPGs).
Maria Rozo, Miriam A. Bornhorst, Angela J. Waanders, Sara Zarnegar‐Lumley, Ashwin Lakshman Koppayi, Lucy A. Godley   +5 more
wiley   +1 more source